Weijia Fang

8.1k total citations · 5 hit papers
139 papers, 4.2k citations indexed

About

Weijia Fang is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Weijia Fang has authored 139 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 91 papers in Oncology, 32 papers in Molecular Biology and 31 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Weijia Fang's work include Cancer Immunotherapy and Biomarkers (40 papers), Colorectal Cancer Treatments and Studies (27 papers) and Pancreatic and Hepatic Oncology Research (17 papers). Weijia Fang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (40 papers), Colorectal Cancer Treatments and Studies (27 papers) and Pancreatic and Hepatic Oncology Research (17 papers). Weijia Fang collaborates with scholars based in China, United States and Taiwan. Weijia Fang's co-authors include Shuiguang Deng, Jianwei Yin, Hailiang Zhao, Albert Y. Zomaya, Schahram Dustdar, Peng Zhao, Yi Zheng, Hangyu Zhang, Weiqin Jiang and Zhou Tong and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Weijia Fang

130 papers receiving 4.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Edge Intelligence: The Confluence of Edge Computing and Artificial Intelligence

2020 655 citations Shuiguang Deng, Hailiang Zhao et al. IEEE Internet of Things Journal profile →
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

2020 418 citations Yuxian Bai, Weijia Fang et al. profile →
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

2019 392 citations Yi Zheng, Tingting Wang et al. Journal for ImmunoTherapy of Cancer profile →
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

2022 127 citations Weijia Fang, Yuxian Bai et al. profile →
Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment

2024 68 citations Yuzhi Jin, Hangyu Zhang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weijia Fang China	32	1.7k	1.1k	748	715	592	139	4.2k
Won Suk Lee South Korea	29	1.3k 0.8×	817 0.7×	242 0.3×	496 0.7×	722 1.2×	121	3.3k
Takeshi Suda Japan	39	977 0.6×	2.3k 2.1×	912 1.2×	457 0.6×	1.1k 1.8×	212	5.8k
Takafumi Yoshida Japan	35	1.3k 0.8×	1.1k 1.0×	710 0.9×	243 0.3×	848 1.4×	130	5.1k
Guo‐Ping Jiang China	43	941 0.5×	986 0.9×	347 0.5×	190 0.3×	750 1.3×	392	6.8k
Andrea Buda Italy	32	691 0.4×	1.1k 1.0×	222 0.3×	436 0.6×	236 0.4×	115	3.5k
Jun Han China	34	433 0.3×	1.2k 1.1×	776 1.0×	329 0.5×	131 0.2×	275	4.3k
Dorothea Wagner Germany	28	1.8k 1.0×	794 0.7×	151 0.2×	2.2k 3.1×	222 0.4×	152	4.4k
Eric P. Sandgren United States	38	2.1k 1.2×	2.5k 2.3×	879 1.2×	239 0.3×	500 0.8×	125	6.9k
Joon Seong Park South Korea	30	1.7k 1.0×	402 0.4×	209 0.3×	952 1.3×	114 0.2×	169	3.1k
Michael Elkin Israel	48	805 0.5×	3.9k 3.5×	121 0.2×	343 0.5×	353 0.6×	164	7.5k

Countries citing papers authored by Weijia Fang

Since Specialization

Citations

This map shows the geographic impact of Weijia Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weijia Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weijia Fang more than expected).

Fields of papers citing papers by Weijia Fang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weijia Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weijia Fang. The network helps show where Weijia Fang may publish in the future.

Co-authorship network of co-authors of Weijia Fang

This figure shows the co-authorship network connecting the top 25 collaborators of Weijia Fang. A scholar is included among the top collaborators of Weijia Fang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weijia Fang. Weijia Fang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ли, Бин, Hangyu Zhang, Yang Gao, et al.. (2025). NKG2D CAR-NK adoptive cellular immunotherapy combined with or without PD-1 blockade in the treatment of patients with metastatic colorectal cancer: an exploratory study. Cancer Immunology Immunotherapy. 74(11). 341–341. 1 indexed citations

Zheng, Bingzhu, Xiaomeng Dai, Jingya Li, et al.. (2025). Amplifying Anti‐Tumor Immune Responses via Mitochondria‐Targeting Near‐Infrared Photodynamic Therapy. Advanced Science. 12(33). e05525–e05525. 3 indexed citations

Liu, Qisha, Jingjing Wang, Yutong Yao, et al.. (2025). Intratumor Rhodococcus sp. B513 drives DEN-induced hepatocellular carcinoma progression by modulating gut microbiota and angiogenesis. Current Research in Microbial Sciences. 9. 100428–100428.

Sun, Xuqi, Chuan Liu, Weihong Tian, et al.. (2024). A Pathologically Friendly Strategy for Determining the Organ‐specific Spatial Tumor Microenvironment Topology in Lung Adenocarcinoma Through the Integration of snRandom‐seq and Imaging Mass Cytometry. Advanced Science. 11(26). e2308892–e2308892. 5 indexed citations

Xie, Jindong, Bo Lin, Weihong Tian, et al.. (2024). Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy. Advanced Science. 11(23). e2401061–e2401061. 35 indexed citations

Zhang, Hangyu, Xiaoxuan Tu, Zhou Tong, et al.. (2024). The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient. Cancer Gene Therapy. 31(9). 1412–1426. 10 indexed citations

Cheng, Xiaofei, Kai Han, Xuqi Sun, et al.. (2024). A novel molecular subtyping based on multi-omics analysis for prognosis predicting in colorectal melanoma: A 16-year prospective multicentric study. Cancer Letters. 585. 216663–216663. 5 indexed citations

Tu, Xiaoxuan, Yi Zheng, Chenglin Mu, et al.. (2024). S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function. Journal of Experimental & Clinical Cancer Research. 43(1). 72–72. 8 indexed citations

Fu, Qihan, Yi Zheng, Weijia Fang, et al.. (2023). RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine. 63. 102175–102175. 46 indexed citations

10.

Fu, Xianhua, Jieer Ying, Yang Liu, et al.. (2022). Dual targeted therapy with pyrotinib and trastuzumab forHER2‐positive advanced colorectal cancer: A phase 2 trial. Cancer Science. 114(3). 1067–1074. 20 indexed citations

11.

Shao, Guoliang, Xu Zhu, Weijia Fang, et al.. (2022). Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma. Liver Cancer. 12(2). 116–128. 7 indexed citations

12.

Shi, Jiawei, Junwei Liu, Xiaoxuan Tu, et al.. (2022). Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. Journal for ImmunoTherapy of Cancer. 10(1). e003133–e003133. 58 indexed citations

13.

Chen, Dong, Xuanwen Bao, Ruyi Zhang, et al.. (2021). Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma. British Journal of Cancer. 125(7). 994–1002. 21 indexed citations

14.

Zhang, Xujun, Kefan Bi, Xiaoxuan Tu, et al.. (2021). Interleukin‐33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer. Cancer Medicine. 10(23). 8338–8351. 10 indexed citations

15.

Fan, Juan, Jiawei Shi, Yong Zhang, et al.. (2021). NKG2D discriminates diverse ligands through selectively mechano‐regulated ligand conformational changes. The EMBO Journal. 41(2). e107739–e107739. 36 indexed citations

16.

Deng, Shuiguang, Hailiang Zhao, Weijia Fang, et al.. (2020). Edge Intelligence: The Confluence of Edge Computing and Artificial Intelligence. IEEE Internet of Things Journal. 7(8). 7457–7469. 655 indexed citations breakdown →

17.

Cong, Yan, Xiaoxuan Tu, Wei Wu, et al.. (2019). Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?. World Journal of Clinical Cases. 7(11). 1253–1261. 13 indexed citations

18.

Zheng, Yi, Tingting Wang, Xiaoxuan Tu, et al.. (2019). Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 7(1). 193–193. 392 indexed citations breakdown →

19.

Jiang, Weiqin, Yifei Shen, Yongfeng Ding, et al.. (2017). A naive Bayes algorithm for tissue origin diagnosis (TOD‐Bayes) of synchronous multifocal tumors in the hepatobiliary and pancreatic system. International Journal of Cancer. 142(2). 357–368. 21 indexed citations

20.

Mou, Haibo, Yi Zheng, Peng Zhao, et al.. (2011). Celastrol induces apoptosis in non-small-cell lung cancer A549 cells through activation of mitochondria- and Fas/FasL-mediated pathways. Toxicology in Vitro. 25(5). 1027–1032. 85 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact